ZOM Intrinsic Valuation and Fundamental Analysis - Zomedica Corp - Alpha Spread
Z

Zomedica Corp
AMEX:ZOM

Watchlist Manager
Zomedica Corp
AMEX:ZOM
Watchlist
Price: 0.1298 USD 1.41% Market Closed
Market Cap: 129.5m USD
Have any thoughts about
Zomedica Corp?
Write Note

Intrinsic Value

The intrinsic value of one ZOM stock under the Base Case scenario is 0.1264 USD. Compared to the current market price of 0.1298 USD, Zomedica Corp is Overvalued by 3%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZOM Intrinsic Value
0.1264 USD
Overvaluation 3%
Intrinsic Value
Price
Z
Worst Case
Base Case
Best Case

Valuation Backtest
Zomedica Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZOM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZOM?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Zomedica Corp

Provide an overview of the primary business activities
of Zomedica Corp.

What unique competitive advantages
does Zomedica Corp hold over its rivals?

What risks and challenges
does Zomedica Corp face in the near future?

Has there been any significant insider trading activity
in Zomedica Corp recently?

Summarize the latest earnings call
of Zomedica Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zomedica Corp.

Provide P/S
for Zomedica Corp.

Provide P/E
for Zomedica Corp.

Provide P/OCF
for Zomedica Corp.

Provide P/FCFE
for Zomedica Corp.

Provide P/B
for Zomedica Corp.

Provide EV/S
for Zomedica Corp.

Provide EV/GP
for Zomedica Corp.

Provide EV/EBITDA
for Zomedica Corp.

Provide EV/EBIT
for Zomedica Corp.

Provide EV/OCF
for Zomedica Corp.

Provide EV/FCFF
for Zomedica Corp.

Provide EV/IC
for Zomedica Corp.

Show me price targets
for Zomedica Corp made by professional analysts.

What are the Revenue projections
for Zomedica Corp?

How accurate were the past Revenue estimates
for Zomedica Corp?

What are the Net Income projections
for Zomedica Corp?

How accurate were the past Net Income estimates
for Zomedica Corp?

What are the EPS projections
for Zomedica Corp?

How accurate were the past EPS estimates
for Zomedica Corp?

What are the EBIT projections
for Zomedica Corp?

How accurate were the past EBIT estimates
for Zomedica Corp?

Compare the revenue forecasts
for Zomedica Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zomedica Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zomedica Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zomedica Corp compared to its peers.

Compare the P/E ratios
of Zomedica Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Zomedica Corp with its peers.

Analyze the financial leverage
of Zomedica Corp compared to its main competitors.

Show all profitability ratios
for Zomedica Corp.

Provide ROE
for Zomedica Corp.

Provide ROA
for Zomedica Corp.

Provide ROIC
for Zomedica Corp.

Provide ROCE
for Zomedica Corp.

Provide Gross Margin
for Zomedica Corp.

Provide Operating Margin
for Zomedica Corp.

Provide Net Margin
for Zomedica Corp.

Provide FCF Margin
for Zomedica Corp.

Show all solvency ratios
for Zomedica Corp.

Provide D/E Ratio
for Zomedica Corp.

Provide D/A Ratio
for Zomedica Corp.

Provide Interest Coverage Ratio
for Zomedica Corp.

Provide Altman Z-Score Ratio
for Zomedica Corp.

Provide Quick Ratio
for Zomedica Corp.

Provide Current Ratio
for Zomedica Corp.

Provide Cash Ratio
for Zomedica Corp.

What is the historical Revenue growth
over the last 5 years for Zomedica Corp?

What is the historical Net Income growth
over the last 5 years for Zomedica Corp?

What is the current Free Cash Flow
of Zomedica Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zomedica Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zomedica Corp

Current Assets 92.1m
Cash & Short-Term Investments 83m
Receivables 2.4m
Other Current Assets 6.7m
Non-Current Assets 151.6m
Long-Term Investments 8m
PP&E 26.2m
Intangibles 116.4m
Other Non-Current Assets 1.1m
Current Liabilities 8m
Accounts Payable 6.7m
Accrued Liabilities 913k
Other Current Liabilities 419k
Non-Current Liabilities 3.8m
Other Non-Current Liabilities 3.8m
Efficiency

Earnings Waterfall
Zomedica Corp

Revenue
26m USD
Cost of Revenue
-8.4m USD
Gross Profit
17.6m USD
Operating Expenses
-63.7m USD
Operating Income
-46.1m USD
Other Expenses
8.8m USD
Net Income
-37.3m USD

Free Cash Flow Analysis
Zomedica Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZOM Profitability Score
Profitability Due Diligence

Zomedica Corp's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROIC is Increasing
Exceptional Revenue Growth Forecast
35/100
Profitability
Score

Zomedica Corp's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

ZOM Solvency Score
Solvency Due Diligence

Zomedica Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Zomedica Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZOM Price Targets Summary
Zomedica Corp

Wall Street analysts forecast ZOM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZOM is 0.44 USD .

Lowest
Price Target
Not Available
Average
Price Target
0.44 USD
239% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZOM?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for ZOM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about ZOM dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

ZOM Price
Zomedica Corp

1M 1M
-5%
6M 6M
-4%
1Y 1Y
-27%
3Y 3Y
-74%
5Y 5Y
-68%
10Y 10Y
-84%
Annual Price Range
0.1298
52w Low
0.1223
52w High
0.2198
Price Metrics
Average Annual Return -16.52%
Standard Deviation of Annual Returns 27.95%
Max Drawdown -95%
Shares Statistics
Market Capitalization 127.2m USD
Shares Outstanding 997 950 016
Percentage of Shares Shorted 5.93%

Competitive Landscape

Ownership

ZOM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Zomedica Corp

Country

United States of America

Industry

Health Care

Market Cap

127.2m USD

Dividend Yield

0%

Description

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 85 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

Contact

MICHIGAN
Ann Arbor
100 Phoenix Drive, Suite 125
+17343692555
zomedica.com

IPO

2013-10-28

Employees

85

Officers

See Also

Discover More
What is the Intrinsic Value of one ZOM stock?

The intrinsic value of one ZOM stock under the Base Case scenario is 0.1264 USD.

Is ZOM stock undervalued or overvalued?

Compared to the current market price of 0.1298 USD, Zomedica Corp is Overvalued by 3%.

Back to Top